Please use this identifier to cite or link to this item:
|Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news.
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Renal Cell
Clinical Trials, Phase III as Topic
Immune Checkpoint Inhibitors
Randomized Controlled Trials as Topic
|Cancer Treat Rev.2021;(99):102239
|Immune-checkpoint inhibitor-based therapy has revolutionized the natural history of metastatic renal cell carcinoma (mRCC) providing better survival outcomes, higher rates of complete responses (CR) and durable remissions. Along with these advances, new challenges have emerged. RECIST and new immune-response criteria may be equivocal identifying complete responses. How to define a durable response and what is the optimal treatment duration remains unclear. Furthermore, the real value of a complete and deep response, whether or not it can be considered curation and whether or not immunotherapy discontinuation should be considered after complete response, are questions that remain open. The present article reviews the current evidence regarding the impact and challenges of managing complete and durable responses in mRCC treated with immune-checkpoint inhibitors.
|Appears in Collections:
|Hospitales > H. U. 12 de Octubre > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. 12 de Octubre > Artículos
Fundaciones e Institutos de Investigación > FIIB H. U. Infanta Sofía y H. U. Henares > Artículos
Hospitales > H. U. Infanta Sofía > Artículos
Files in This Item:
The file with the full text of this item is not available due to copyright restrictions or because there is no digital version. Authors can contact the head of the repository of their center to incorporate the corresponding file.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.